Journal of Cancer Prevention

eISSN 2288-3657
pISSN 2288-3649

Univariate and multivariate analyses of baseline characteristic subgroups and PFS in 43 patients with metastatic CRC

Characteristic Median PFS (95% CI) Univariate analyses
(P-value)
Multivariate analyses
HR (95% CI) P-value
Age (yr) 0.616
≥ 63 6.0 (3.91-8.09)
< 63 5.8 (4.03-7.57)
ECOG PS score 0.011 0.75 (0.38-0.91) 0.029
0-1 6.5 (4.15-8.85)
2 4.9 (3.82-5.98)
Sex 0.413
Male 5.0 (3.72-6.28)
Female 6.0 (4.18-7.82)
Pathological stage 0.318
IIIb 6.5 (4.31-8.69)
IV 5.8 (4.04-7.56)
Primary tumor site 0.009 1.43 (1.09-1.93) 0.015
Right 4.5 (3.37-5.63)
Left or rectum 6.5 (4.18-8.82)
Previous systemic treatment 0.511
Second line 6.0 (4.27-7.73)
Third line and above 5.8 (4.02-7.58)
Surgical treatment history 0.325
Yes 6.0 (4.13-7.87)
No 5.8 (3.94-7.66)
MMR status
dMMR 6.5 (4.82-8.18) 0.335
pMMR 5.0 (3.85-6.15)
Unknown 5.8 (4.11-7.49)
Number of metastases sites 0.218
≤ 3 6.0 (4.35-7.65)
> 3 5.0 (3.82-6.18)
Liver metastases 0.331
Yes 5.8 (4.18-7.42)
No 6.0 (4.09-7.91)
Initial dosage of apatinib (mg) 0.235
250 5.0 (3.89-6.11)
500 5.8 (4.03-7.57)
PD-1 blockades 0.418
Camrelizumab 5.0 (3.78-6.22)
Sintilimab 5.8 (4.06-7.54)
Pembrolizumab 6.0 (4.36-7.64)

PFS, progression free survival; CRC, colorectal cancer; ECOG, Eastern Cooperative Oncology Group; PS, performance status; HR, hazard ratio; MMR, mismatch repair; dMMR, mismatch repair-deficient; pMMR, proficient mismatch repair; PD-1, programmed cell death protein 1.

J Cancer Prev 2023;28:106~114 https://doi.org/10.15430/JCP.2023.28.3.106
© J Cancer Prev
© Korean Society of Cancer Prevention. / Powered by INFOrang Co., Ltd